Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Immuron Reports Double‑Digit Q3 Sales Growth for Travelan
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$7.80M |
$0.60
+1.42%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$7.59M |
$1.69
+3.68%
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$7.42M |
$1.05
+65.48%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB develops oncology-focused cell-based therapies (Cell-in-a-Box encapsulation) aligned with Biotech - Oncology.
|
$7.38M |
$0.73
-0.19%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$7.02M |
$3.11
-2.20%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$7.01M |
$0.74
-0.52%
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$6.98M |
$0.79
-0.65%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$6.94M |
$0.44
-1.77%
|
|
ACUT
Accustem Sciences Inc.
Tests and technologies are oncology-focused biomarker diagnostics, placing ACUT in the oncology diagnostics space.
|
$6.93M |
$0.43
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$6.67M |
$1.44
-1.03%
|
|
ICU
SeaStar Medical Holding Corporation
QUELIMMUNE represents an immunology therapeutic, aligning with Immunology Therapeutics.
|
$6.64M |
$2.36
-0.84%
|
|
BMRA
Biomerica, Inc.
Offers Contract Manufacturing services with notable growth, i.e., contract manufacturing revenue stream.
|
$6.58M |
$2.20
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$6.56M |
$0.85
+1.50%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$6.37M |
$2.42
+3.86%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$6.33M |
$0.89
-1.61%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$6.21M |
$0.68
-11.17%
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$6.14M |
$1.07
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$6.09M |
$0.45
-5.73%
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.03M |
$5.04
+0.80%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$5.94M |
$2.66
+1.14%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$5.62M |
$0.76
+0.68%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$5.60M |
$0.95
+12.38%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$5.49M |
$0.84
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$5.47M |
$1.17
-4.88%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$5.34M |
$0.90
+2.67%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$5.29M |
$7.29
+7.05%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.07M |
$1.55
-0.26%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$5.05M |
$0.19
-0.32%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$4.96M |
$2.37
-4.82%
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$4.94M |
$5.46
-2.67%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$4.60M |
$1.24
-1.20%
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$4.56M |
$0.36
+2.19%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$4.42M |
$0.04
|
|
XAIR
Beyond Air, Inc.
UNO program for solid tumors places Beyond Air in oncology-focused biotech pipelines.
|
$4.36M |
$0.53
+19.16%
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$4.32M |
$5.94
-0.17%
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$4.26M |
$1.11
+11.00%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$4.14M |
$1.24
-0.40%
|
Showing page 23 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
